1. Home
  2. EPOW vs GBIO Comparison

EPOW vs GBIO Comparison

Compare EPOW & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EPOW

Sunrise New Energy Co. Ltd

HOLD

Current Price

$0.82

Market Cap

35.0M

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.34

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPOW
GBIO
Founded
2014
2016
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.0M
36.3M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
EPOW
GBIO
Price
$0.82
$5.34
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.88
AVG Volume (30 Days)
144.0K
133.1K
Earning Date
05-15-2025
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$70,681,651.00
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
51.60
N/A
52 Week Low
$0.66
$3.00
52 Week High
$1.86
$8.40

Technical Indicators

Market Signals
Indicator
EPOW
GBIO
Relative Strength Index (RSI) 45.04 39.79
Support Level $0.73 $5.47
Resistance Level $0.82 $5.77
Average True Range (ATR) 0.07 0.17
MACD 0.00 -0.02
Stochastic Oscillator 58.21 0.00

Price Performance

Historical Comparison
EPOW
GBIO

About EPOW Sunrise New Energy Co. Ltd

Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is in the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: